Loading clinical trials...
Loading clinical trials...
To identify the Maximum Tolerated Dose levels of LEO 43204 after once daily treatment for two consecutive days and to evaluate efficacy of LEO 43204 in two doses after once daily treatment for two con...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
LEO Pharma
NCT07340697 · Actinic Keratosis (AK)
NCT07318675 · Actinic Keratosis (AK)
NCT06778434 · Actinic Keratosis, Imipramine, and more
NCT07137819 · Actinic Keratosis of Face and Scalp
NCT06648447 · Actinic Keratosis (AK)
Gwinnett Clinical Research Center, Inc.
Snellville, Georgia
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions